Literature DB >> 8818515

Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes.

M A Austin1, K L Edwards.   

Abstract

The role of small, dense LDL as a risk factor for coronary heart disease is becoming well established. Several atherogenic mechanisms have been proposed to explain this relationship, including the association of small, dense LDL with the insulin resistance syndrome. A variety of studies, including large epidemiologic investigations, have now demonstrated that a predominance of small, dense LDL is one of the constellation of interrelated risk factors that characterize the insulin resistance syndrome. Recent results using a multivariate factor analysis approach have also shown that this set of risk factors can be simplified into three or four uncorrelated components that may provide new insights into the mechanisms underlying the syndrome and its association with disease. Furthermore, a number of cross-sectional studies and one prospective study have shown that small, dense LDL is a risk factor for noninsulin-dependent diabetes itself, and that this association may also be attributable to the insulin resistance syndrome.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8818515     DOI: 10.1097/00041433-199606000-00010

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  19 in total

1.  Combined oestrogen-progestogen replacement therapy does not inhibit low-density lipoprotein oxidation in postmenopausal women.

Authors:  Y Wen; M C Doyle; L A Norris; M M Sinnott; T Cooke; R F Harrison; J Feely
Journal:  Br J Clin Pharmacol       Date:  1999-03       Impact factor: 4.335

2.  Very low-density lipoprotein apolipoprotein B-100 turnover in glycogen storage disease type Ia (von Gierke disease).

Authors:  A S Wierzbicki; G F Watt; J Lynas; A F Winder; R Wray
Journal:  J Inherit Metab Dis       Date:  2001-10       Impact factor: 4.982

3.  Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.

Authors:  Makoto Kinoshita; Koutaro Yokote; Hidenori Arai; Mami Iida; Yasushi Ishigaki; Shun Ishibashi; Seiji Umemoto; Genshi Egusa; Hirotoshi Ohmura; Tomonori Okamura; Shinji Kihara; Shinji Koba; Isao Saito; Tetsuo Shoji; Hiroyuki Daida; Kazuhisa Tsukamoto; Juno Deguchi; Seitaro Dohi; Kazushige Dobashi; Hirotoshi Hamaguchi; Masumi Hara; Takafumi Hiro; Sadatoshi Biro; Yoshio Fujioka; Chizuko Maruyama; Yoshihiro Miyamoto; Yoshitaka Murakami; Masayuki Yokode; Hiroshi Yoshida; Hiromi Rakugi; Akihiko Wakatsuki; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2018-08-22       Impact factor: 4.928

Review 4.  Strategies for the management of diabetic dyslipidaemia.

Authors:  M R Taskinen
Journal:  Drugs       Date:  1999       Impact factor: 9.546

5.  Fenofibrate protects lipoproteins from lipid peroxidation: synergistic interaction with alpha-tocopherol.

Authors:  E Chaput; D Maubrou-Sanchez; F D Bellamy; A D Edgar
Journal:  Lipids       Date:  1999-05       Impact factor: 1.880

Review 6.  Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials.

Authors:  João Costa; Margarida Borges; Cláudio David; António Vaz Carneiro
Journal:  BMJ       Date:  2006-04-03

7.  Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease.

Authors:  Minako Yamaoka-Tojo; Taiki Tojo; Naonobu Takahira; Atsuhiko Matsunaga; Naoyoshi Aoyama; Takashi Masuda; Tohru Izumi
Journal:  Cardiovasc Diabetol       Date:  2010-05-14       Impact factor: 9.951

Review 8.  Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies.

Authors:  Christina Voulgari; Dimitrios Papadogiannis; Nicholas Tentolouris
Journal:  Vasc Health Risk Manag       Date:  2010-10-21

9.  Effect of glycated LDL on microvascular tone in mice: a comparative study with LDL modified in vitro or isolated from diabetic patients.

Authors:  P Nivoit; N Wiernsperger; P Moulin; M Lagarde; C Renaudin
Journal:  Diabetologia       Date:  2003-10-24       Impact factor: 10.122

10.  Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men.

Authors:  J Kellogg Parsons; Jaclyn Bergstrom; Elizabeth Barrett-Connor
Journal:  BJU Int       Date:  2007-11-13       Impact factor: 5.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.